Not recruiting yet
Intracavernosal Exosomes vs. Rectal Ozone for Post-RARP Erectile Dysfunction
NCT07707505 · Medipol University · Updated 16 July 2026
- What is being tested
- Urine-Derived Exosomes (USC-Exos); Rectal Medical Ozone Insufflation; Daily Phosphodiesterase type 5 (PDE5) Inhibitor
- For
- Erectile Dysfunction Following Radical Prostatectomy
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 45 years to 75 years. About 60 people. The full rules are on the registry page.
- Where
- Turkey (Türkiye)
- When
- Starts or started 1 Aug 2026, ends 1 April 2027. Registered 16 July 2026.
- Results
- None posted yet.
In the researchers' words
This prospective, randomized, controlled trial aims to evaluate and compare the therapeutic efficacy of intracavernosal urine-derived exosomes and systemic rectal ozone therapy in patients experiencing erectile dysfunction (ED) post-robotic-assisted radical prostatectomy (RARP). Patients will be randomized into two distinct intervention arms. The primary objective is to assess the functional recovery of the erectile tissue via the International Index of Erectile Function (IIEF-5) over a 6-month follow-up period. Secondary endpoints include penile hemodynamic alterations and overall health-related quality of life.
Sites
- Başakşehir Çam Sakura City HospitalIstanbul, Başakşehir, Turkey (Türkiye)